Market News & Trends
Catalent Biologics & Triphase Accelerator Corporation Announce License Agreement to Advance SMARTag
Catalent and Triphase Accelerator Corporation recently announced that Triphase will obtain worldwide rights to further develop Catalent’s proprietary CD22-4AP Antibody-Drug Conjugate (ADC), which has been…
Global Market for Glycobiology to Reach Double Digit CAGRS in All Segments
New tools for synthesizing, modifying and studying oligosaccharides and glycoconjugates are charging the global glycobiology market. BCC Research reveals in its new report, Glycobiology: Global…
Cardiovascular Disease Market Set to Grow Very Slowly to $146.4 Billion
The cardiovascular disease market, which includes hypertension, dyslipidemia, and thrombotic events, is set to grow from $129.2 billion in 2015 to $146.4 billion by 2022,…
AB BioTechnologies Expands Services With Addition of Preclinical Manufacturing Capabilities
AB BioTechnologies, Inc. recently announced it is expanding its services to include preclinical manufacturing at its Bloomington, IN, facility. New drug candidates must undergo preclinical…
Orbus Therapeutics Announces Enrollment of First Patient in Phase III Trial
Orbus Therapeutics Inc. recently announced that the first patient has been enrolled in a pivotal Phase III clinical trial, called STELLAR, of eflornithine in patients…
MilliporeSigma Launches Viresolve® Pro Shield H
MilliporeSigma recently launched the Viresolve® Pro Shield H for removal of parvoviruses from therapeutic protein feed streams. The new Viresolve Pro Shield H is designed…
Lipocine Announces Positive Top-Line Phase IIb Study Results
Lipocine Inc. recently reported positive top-line results from a Phase IIb clinical study of LPCN 1111, a novel oral testosterone replacement therapy (TRT) product candidate.…
Capsugel Launches Vcaps for Enteric Protection & Delayed Release
Capsugel recently announced the launch of its Vcaps® Enteric capsules, a new functional capsule technology that achieves enteric protection and delayed release without the need…
Cambrex to Acquire Pharmacore to Expand Capabilities
Cambrex Corporation recently announced it has agreed to acquire PharmaCore Inc. for approximately $25 million. PharmaCore was founded in 1999 and occupies a 35,000-sq-ft GMP…
Gastrointestinal Drugs Market to Hit $48.4 Billion
The market size for gastrointestinal therapeutics is set to grow from $35.7 billion in 2015 to $48.4 billion by 2022, representing a compound annual growth…
Lupin Pharmaceutical Inc. & MonoSol Rx Enter Strategic Licensing Agreement to Develop Multiple Products
Lupin Pharmaceutical Inc., the US subsidiary of pharma major Lupin Limited (collectively Lupin) and MonoSol Rx, a specialty pharmaceutical company have entered into a strategic…
Biologics Candidate Manufactured Using Ajinomoto’s CORYNEX® Protein Expression System Enters Clinical Trials for the First Time
Ajinomoto Althea, Inc. (Althea) announced that a biologics candidate developed by a Japanese global pharmaceutical company and manufactured at Ajinomoto Althea using CORYNEX® Protein Expression…
Adare Pharmaceuticals Celebrates Corporate Headquarters Grand Opening
Adare Pharmaceuticals, a private global specialty pharmaceutical company, celebrated the official opening of its Corporate Headquarters located at 1200 Lenox Drive in Lawrenceville, New Jersey.…
"Engineering Medicines to Life" Campaign Highlights Capsugel's Unique Positioning as Specialty CDMO
After successfully completing four transformational acquisitions, as well as several other strategic investments, Capsugel today announced that it has unified them all under one brand…
Bristol-Myers Squibb & Nektar Therapeutics Announce Oncology Clinical Collaboration
Bristol-Myers Squibb Company and Nektar Therapeutics recently announced a new clinical collaboration to evaluate Bristol-Myers Squibb's Opdivo (nivolumab) with Nektar's investigational medicine, NKTR-214, as a…
Mucodel Pharma Announces Successful Completion of Buccal Naloxone Pilot Clinical Study
Mucodel Pharma LLC recently announced the successful completion of a pilot clinical study involving buccal naloxone (Exonal), a Mucodel product under development for the reversal…
Madrigal Pharmaceuticals & Tarveda Therapeutics Announce Exclusive License Agreement
Madrigal Pharmaceuticals, Inc. and Tarveda Therapeutics, Inc. recently announced an exclusive worldwide license agreement providing for the discovery, development, and commercialization by Tarveda of products…
ERT Recognized for Patient-Focused Technological Development in Clinical Trials
ERT, a leading provider of high-quality patient data collection solutions for use in clinical drug development, recently announced it has been named a finalist for…
Caladrius Subsidiary, PCT, Announces 5-Year Strategic Manufacturing Services Agreement
Caladrius Biosciences, Inc., a cell therapy company combining an industry-leading development and manufacturing services provider (PCT, LLC, A Caladrius Company) with a select therapeutic development…
Allergan to Acquire Tobira Therapeutics, Expanding Global GI R&D Pipeline & Taking a Leading R&D Position in NASH
Allergan plc recently announced it has entered into a definitive agreement under which Allergan will acquire Tobira for an upfront payment of $28.35 per share,…
